Key facts
- Simile, an AI startup, has raised $200 million in a Series B funding round.
- The startup achieved a $2 billion valuation in its latest funding round.
- This Series B round occurred five months after Simile announced a $100 million Series A.
- The Series B round was led by Greenoaks.
- CVS Health Ventures participated in the funding round, and CVS is a customer of Simile.
Simile, a startup developing AI-powered simulated users for marketing and product research, has announced a $200 million Series B funding round, valuing the company at $2 billion. This significant funding comes just five months after the company emerged from stealth with a $100 million Series A round led by Index Ventures.
The latest Series B round was led by Greenoaks and included participation from existing investors Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition, and CVS Health Ventures. CVS Health Ventures' participation is notable as CVS is also a key customer of Simile.
Founded by Stanford PhD graduate Joon Sung Park, Simile's technology is based on his dissertation project, "Smallville," which involved AI agents simulating human lives. The startup's mission is to simulate "all eight billion people on earth, accurately and honestly," a goal that, while ambitious, points to the growing interest in AI-driven market research and product development.
Simile operates in a burgeoning sector, with other startups like Aaru also attracting substantial venture capital, indicating strong investor confidence in AI-driven user simulation for research and product mock-ups.